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1ProCure Program, IDIBELL-Institut Català d’Oncologia, L’Hospitalet de Llobregat, Barcelona, SpainTo enhance adenovirus-mediated oncolysis, different ap-
proaches that tackle the selectivity, tumor penetration, and
spreading potential of oncolytic adenoviruses have been re-
ported. We have previously demonstrated that insertion of
the internalizing Arginine-Glycine-Aspartic (iRGD) tumor-
penetrating peptide at the C terminus of the fiber or transgenic
expression of a secreted hyaluronidase can improve virus tu-
mor targeting and spreading. Here we report a new oncolytic
adenovirus ICOVIR17K-iRGD in which both modifications
have been incorporated. In xenografted A549 tumors in nude
mice, ICOVIR17K-iRGD shows higher efficacy than the non-
iRGD counterpart. To gain insights into the role of the immune
system in oncolysis, we have studied ICOVIR17K-iRGD in the
tumor isograft mouse model CMT64.6, partially permissive to
human adenovirus 5 replication, in immunodeficient or immu-
nocompetent mice. Whereas no efficacy was observed in the
immunodeficient setting due to insufficient viral replication,
partial efficacy and a polymorphonuclear and CD8+ T cell infil-
trate were observed in the immunocompetent mice. The results
indicate that the elicitation of a virus-induced anti-tumoral im-
mune response is responsible for the observed partial anti-
tumoral effect.Received 2 August 2017; accepted 25 January 2018;
https://doi.org/10.1016/j.omto.2018.01.003.
Correspondence: Ramon Alemany, IDIBELL-Institut Català d’Oncologia, Av.
Gran Via de l’Hospitalet 199-203, L’Hospitalet de Llobregat, 08907 Barcelona,
Spain.
E-mail: ralemany@iconcologia.netINTRODUCTION
Growing clinical evidence indicates that adenoviruses are promising
agents for cancer treatment. Adenovirus type 5 (Ad5), the serotype
most widely used as an oncolytic agent, has been genetically modified
with tumor-targeting ligands, promoters, and mutations that confer
selectivity and with sequences encoding for genes (also known as
armed oncolytic viruses) that increase their anti-tumor activity.1
Our group has described several of these modifications by means of
a virus platform that tackles the constitutively active retinoblastoma
pathway in tumor cells.2 The ICOVIR15K adenovirus harbors three
modifications: a deletion of the pRB-binding site of E1A (delta24
mutation) and the insertion of E2F sites in the E1a promoter for
tumor-selective replication, and the replacement of the KKTK motif
of the fiber shaft with RGDK for tumor targeting. Further modifica-
tions have been put forward by introducing different transgenes con-
nected to the major late promoter by means of a splicing acceptor.2 As
an example, ICOVIR17K (also known as VCN-01) is an oncolytic62 Molecular Therapy: Oncolytics Vol. 8 March 2018 ª 2018 The Autho
This is an open access article under the CC BY license (http://creativadenovirus derived from ICOVIR15K armed with the secreted hyal-
uronidase gene to enhance virus spreading within the tumor mass.
Hyaluronidase is expressed using a splicing acceptor that links its
expression to the major late promoter. This virus has shown favorable
safety and efficacy profiles in several preclinical models and is being
evaluated in clinical trials.3,4 In another modification aimed at
improving tumor targeting and penetration, we have incorporated
the internalizing Arginine-Glycine-Aspartic (iRGD) peptide into
the C terminus of the ICOVIR15K fiber as a fiber-iRGD fusion pro-
tein, resulting in ICOVIR15K-iRGD. The iRGD peptide with the
sequence CRGDKGPDC is a cyclic peptide identified in an in vivo
phage-display screening for peptides able to extravasate tumor blood
vessels in ametastatic tumormodel.5 It has been shown that the iRGD
peptide targets the tumor vasculature via RGD motif-mediated bind-
ing to avb3- and avb5-integrins expressed on tumor endothelial cells.
After binding to these integrins, a proteolysis mediated by an un-
known protease results in exposure of a cryptic arginine-rich peptide
motif (R/KXXR/K) that when present as a C terminus (C-end rule) is
able to bind to neurophillin-1 (NRP1). NRP1 is overexpressed on
angiogenic blood vessels and tumor cells, and iRGD binding to
NRP1 activates an endocytic pathway that leads to tumor penetration
of iRGD, as well as drugs coadministered or conjugated with iRGD.
When the iRGD sequence is fused to the C terminus of a protein, it
is able to promote its tumor penetration. We have reported that in-
serting the iRGD sequence at the C terminus of the fiber as a fusion
fiber-iRGD protein in the oncolytic adenovirus ICOVIR15K en-
hances virus targeting and penetration, resulting in a remarkable
anti-cancer effect.6
Here we report the fusion of iRGD at the C terminus of the fiber
of a hyaluronidase-armed oncolytic adenovirus, generating
ICOVIR17K-iRGD. With these two modifications, we aim to simul-























































































VCN-01 0.1386 ± 0.03
ICOVIR17K-iRGD 0.04435 ± 0.004
Figure 1. In Vitro Characterization of iRGD-Modified Adenoviruses
(A) The cell lines A549 and CMT64.6 were infected with the indicated GFP-expressing vectors at different MOIs, GFP was measured after 24 hr by flow cytometry, and the
percentage of GFP-positive cells is plotted for each vector. The vectors share the same expression cassette containing GFP and luciferase transgenes. Mean ± SD error bars
are plotted. Significant difference between the vectors (*p < 0.05, **p% 0.01) was calculated by two-tailed unpaired Student’s t test. (B) Viral production of ICOVIR17K-iRGD.
A549 and CMT64.6 cells were infected with ICOVIR17K or ICOVIR17K-iRGD at the indicated time points, and cell extracts were harvested and titrated. Three replicates were
quantified for each cell line. Mean ± SD of triplicates is shown. (C) Comparative cytotoxicity in vitro of ICOVIR17K and ICOVIR17K-iRGD. A549 cells were infected with the
indicated viruses at doses starting from 200 TU/cell. IC50 values (TU per cell required to cause a reduction of 50% in cell culture viability) at day 6 after infection are shown. Four
replicates were quantified. Mean ± SD of triplicates is shown.
www.moleculartherapy.orgdissemination with hyaluronidase. We have studied the efficacy
conferred by these modifications in immunodeficient, as well as
immunocompetent, mouse models.
Because fully immunocompetent models require engraftment of
isogenic murine tumor cells and adenoviruses are species specific,
immunotherapy studies with human oncolytic adenoviruses in
immunocompetent mice have been difficult to perform.7 To over-
come this limitation, we have described a murine cell line clone,
CMT64.6, derived from the CMT64 murine lung adenocarcinoma
cell line of C57BL/6 mice, which is semi-permissive to human adeno-
virus replication.8 Here we explore the anti-tumor activity of the new
generated virus ICOVIR17K-iRGD in this model. In addition, given
that immune responses to tumor antigens secondary to oncolysis
can be affected by the route of adenovirus administration, we have
compared the systemic intravenous (i.v.) and intratumoral (i.t.)
administration routes, the two most common routes used in clinical
trials,9 for their ability to induce anti-tumoral immunity.
RESULTS
iRGD Enhances the Infectivity and Cytotoxicity of RGDK-
Modified Adenoviruses
To check the effect of iRGD modification on virus infectivity in
CMT64.6, a subclone of CMT64 selected for higher adenovirus pro-duction levels,8 we performed an infectivity assay with luciferase and
GFP-expressing non-replicative vectors AdGLK and AdGLK-iRGD.
Analysis by flow cytometry 24 hr post-infection showed that insertion
of iRGD increased viral infectivity (Figure 1A). However, CMT64.6
cells were infected less efficiently than the human reference A549
lung adenocarcinoma cell line, which is widely used to characterize
adenoviruses;10 for example, at an MOI of 5, 90% of A549 cells
were infected, whereas at an MOI of 50, only 50% of CMT64.6 cells
were infected.
Having observed the advantage of iRGD in the GFP-luciferase vector
setting, we then inserted iRGD at the C terminus of the hyaluroni-
dase-armed ICOVIR17K virus, using the same methods as described
for ICOVIR15K-iRGD.6 A virus production assay was performed at
different time points in the A549 and CMT64.6 cell lines (Figure 1B).
Whereas A549 produced approximately 104 transducing units
(TUs)/cell, CMT64.6 produced 5 TU/cell, confirming previous
results.8 To determine whether ICOVIR17K retains its oncolytic
properties after iRGD modification, a dose-response cytotoxicity
curve was performed in A549 cells (Figure 1C). The calculated
half-maximal inhibitory concentration (IC50) value of ICOVIR17K-
iRGD was 3.1-fold lower than that of its parental counterpart. This
lower IC50 value indicates that iRGD does not reduce the cytotoxicity
potential of ICOVIR17K.Molecular Therapy: Oncolytics Vol. 8 March 2018 63






























Figure 2. iRGD Improves the Oncolytic Efficacy of ICOVIR17K/VCN-01 in Nude Mice
Nude mice bearing A549 lung carcinoma subcutaneous tumors were systemically treated with a single dose of PBS or 4 1010/mouse of ICOVIR17K or ICOVIR17K-iRGD.
(A) Percentage of tumor growth at the indicated days. Mean ± SEM is plotted (n = 10). Significance (*p < 0.05) by two-tailed unpaired Student’s t test compared with the PBS
group (#p < 0.05) by two-tailed unpaired Student’s t test compared with the ICOVIR17K group. (B) Percentage of tumor growth distribution at the end of the experiment
(day 46).
Molecular Therapy: OncolyticsiRGD Improves the Oncolytic Efficacy of ICOVIR17K
We next investigated the effect of iRGD on the anti-tumor efficacy of
ICOVIR17K. Nude mice bearing human lung adenocarcinoma A549
subcutaneous xenograft tumors were treated systemically via tail vein
with PBS or 4  1010 virus particles (vps)/mouse of ICOVIR17K
or ICOVIR17K-iRGD (Figure 2A), and tumor volume was
measured twice a week during the experiment. Statistical analysis
of tumor growth rate showed significantly improved efficacy of
ICOVIR17K-iRGD compared to PBS-treated mice from day 22
post-treatment until the end of the experiment (46 days) and
compared to ICOVIR17K from day 29 until the end of the experi-
ment. ICOVIR17K-iRGD significantly reduced tumor growth at
the end of the experiment compared to both control groups:
3.6-fold versus ICOVIR17K (p = 0.001) and 5-fold versus PBS
(p = 0.0008) (Figure 2B). Although ICOVIR17K-iRGD did not
lead to complete regression among the 10 tumors measured, 3 tu-
mors partially regressed and 5 tumors remained stable. Given the
strong anti-tumor efficacy of ICOVIR17K-iRGD in nude mice
with fully permissive human tumors, we decided to test its efficacy
in the most challenging setting of immunocompetent mice.
Anti-tumor Efficacy of ICOVIR17K-iRGD in Immunocompetent
Mice
Oncolytic virotherapy with human adenoviruses in immunocompe-
tent mice is limited by poor human adenovirus replication in mouse
cells and fast immune-mediated virus clearance. To palliate the first
problem caused by species-specificity of adenoviruses, we used a mu-
rine cell line, CMT64.6, which is a subclone of CMT64 described by
our group as semi-permissive to adenovirus replication (100-fold
lower virus production than the reference human A549 cell line).8
Mice were treated systemically via tail vein with PBS or 3  1010
vp/mouse of ICOVIR17K-iRGD or ICOVIR17K (Figure 3A).64 Molecular Therapy: Oncolytics Vol. 8 March 2018The ICOVIR17K-iRGD-treated group showed a slower tumor growth
rate compared to the ICOVIR17K and PBS groups, with significant
differences starting at day 3 and lasting until the end of the experi-
ment (day 17), when the tumor size was 1.7-fold lower compared
to ICOVIR17K (p = 0.001) and 2.2-fold lower compared to PBS
(p = 0.001).
At the end of the experiment, tumor sections were stained to detect
virus (E1A protein). At this late stage (day 17), virus was not detected
in tumors, presumably due to immune clearance. However, H&E
staining showed dense infiltration of polymorphonuclear leukocytes
(granulocytes) in the tumors of mice treated with ICOVIR17K-
iRGD and very weak infiltration in ICOVIR17K-treated tumors (Fig-
ure 3B). This experiment confirmed the partial efficacy of
ICOVIR17K-iRGD, in contrast to the lack of efficacy of the parental
ICOVIR17K, in this mouse model (Figure 3A).
To assess the effect of the route of delivery and to gain insights into
the mechanisms of action, we compared i.v. and i.t. administration
routes for anti-tumor efficacy. CMT64.6 subcutaneous tumors were
grown in both flanks of C57BL/6 mice, and mice were treated with
PBS systemically, ICOVIR17K-iRGD systemically, or ICOVIR17K-
iRGD i.t. Virus-treated groups were given a dose of 3  1010
vp/mouse. To explore a contralateral effect potentially associated
with an immune response, i.t. administration was performed in
only one tumor of each mouse. At an early stage of the experiment
(day 3 post-treatment), one mouse from each group was sacrificed
and tumors were kept in paraffin for immunohistochemistry. The re-
maining tumors were collected at the end of the experiment (day 18;
late stage). Tumors were split for immunohistochemistry and im-
mune response studies; spleens were also collected for immune






Figure 3. Anti-tumor Efficacy Comparison of ICOVIR17K and ICOVIR17K-
iRGD in Immunocompetent Mice
C57BL/6 mice bearing CMT64.6 murine lung carcinoma subcutaneous tumors
were systemically treated with a single dose of PBS or 3  1010/mouse of
ICOVIR17K-iRGD or ICOVIR17K. (A) The percentage of tumor growth (mean ±SEM)
at the indicated days is plotted (n = 12). Significance (*p < 0.05) against PBS, and
significance (#p < 0.05) against ICOVIR17K by two-tailed unpaired Student’s t test.
(B) H&E staining for paraffin tumor sections. Nuclei stained in blue correspond to
granulocytes.
www.moleculartherapy.orgcontrol rate regardless of the administration route, which was signif-
icant compared to PBS (Figure 4A). In the i.t.-treated group, injected
and contralateral (non-injected) tumors responded equally (Fig-
ure 4B). We were able to detect virus in tumors at day 3 post-treat-
ment in the i.t. injected tumors, but not in non-injected contralateral
tumors or in tumors from mice treated by the systemic route. At day
18, virus could not be detected in any tumor (Figure 4C). All tumors
from virus-treated mice, irrespective of the day of harvest (day 3 or
day 18) or the route of administration (i.t. or systemic), presented
high polymorphonuclear infiltration.
To evaluate immune infiltration, tumors were disaggregated and di-
gested to prepare cells in suspension, and cells were incubated with
CD45+ and CD8+ antibodies and analyzed by flow cytometry. The
amount of CD45+ T cells detected was similar in all groups, including
the PBS-treated groups. However, we detected a higher level of
tumor-infiltrating CD8+ T cells in the virus-treated groups. Thishigh level of CD8+ T cells was also detected in the non-injected
contralateral tumors of the ICOVIR17K-iRGD i.t. treated mice
(Figure 4D). This observation suggested the viral activation of
tumor-specific CD8+ T cells.
Taking advantage of certain immunogenic neoepitopes derived from
mutations present in CMT64,11 we then assessed the tumor-specific
T cell response in splenocytes by interferon-gamma (IFN-g)-
Enzyme-Linked ImmunoSpot (ELISpot). The exome of our subclone
CMT64.6 was sequenced to check whether it carries the same muta-
tions as the parental model CMT64. Of the seven main immunogenic
mutations detected for CMT64 upon oncolysis with adenovirus,11
three were present in the CMT64.6 subclone (Rab13, Ndufs1, and
Arhgef10). We therefore checked whether treatment with
ICOVIR17K-iRGD induced immune responses to these neoepitopes.
The three neoepitopes were synthesized as minimal binding-motif
peptides and incubated with splenocytes in an IFN-g-ELISpot
assay. The peptide E1B192 and the adenovirus hexon peptide pool
PepTivator were used to detect anti-viral responses. Infected and
non-infected CMT64.6 cells, as live cells or cell lysates, were used to
further discriminate between anti-tumor and anti-viral immune re-
sponses. An anti-tumor immune response was found against the
Nduf1 mutation in one mouse (out of six) treated with the virus i.t.,
suggesting that i.t. administration was better than i.v. administration
at inducing tumor-specific immune responses. Otherwise, the im-
mune response was mainly directed against viral antigens (E1B199,
PepTivator, and infected cells) in mice that had been treated with vi-
ruses, independent of the administration route, pointing at the strong
immunodominance of the virus compared to the tumor neoepitopes
(Figures 4E and 4F).
To further determine the role of the immune system in the observed
partial control of tumor growth, we performed a similar study to
assess virus efficacy in immunocompromised mice. Although the
mouse cell clone CMT64.6 is more permissive to Ad5 than the
parental cell line CMT64, the levels of virus replication are still low
compared to human cells. This limits the oncolytic effect mediated
solely by replication and virus spread in the absence of an immune
response. CMT64.6 subcutaneous tumors were grown in both flanks
of athymic nude mice and treated with ICOVIR17K-iRGD via i.v. or
i.t. administration routes. Tumors were measured twice per week and
collected for immunohistochemistry at the end of the experiment. No
treatment was effective despite the detection of virus i.t. (Figure 5).
The amount of virus observed in tumors was low and localized to a
few areas, indicating that replication was not efficient enough to affect
tumor size. The lack of tumor control in nude mice indicated that the
activity of ICOVIR17K-iRGD against the CMT64.6 graft in C57BL/6
mice was immune mediated.
In summary, the newly generated virus ICOVIR17K-iRGD showed
remarkable efficacy when tested in immunodeficient mice bearing a
fully permissive human tumor xenograft. In contrast, no efficacy
was observed in immunodeficient mice bearing a mouse tumor
isograft due to the limited replication of the virus. However, efficacyMolecular Therapy: Oncolytics Vol. 8 March 2018 65
Figure 4. Anti-tumor Efficacy of Systemic or i.t. Administration of ICOVIR17K-iRGD in Immunocompetent Mice
C57BL/6 mice bearing CMT64.6 murine lung carcinoma subcutaneous tumors were systemically treated with a single dose of PBS or 3 1010/mouse of ICOVIR17K-iRGD.
(A) The percentage of tumor growth (mean ± SEM) at the indicated days is plotted (n = 11–12). Significance (*p < 0.05) by two-tailed unpaired Student’s t test compared with
the PBS group. (B) Comparison of injected and non-injected contralateral tumors of the i.t. mice group. Percentage of tumor growth (mean ± SEM) at the indicated days is
plotted (n = 5–6). (C) Immunohistochemical staining with E1A antibody of representative i.t. injected tumors at day 3 or at day 18 post-injection. (D) Levels of CD45 and
CD45/CD8 cells in tumors frommice treated i.v. or i.t. (injected and non-injected contralateral tumors). Tumors were mechanically disaggregated and incubated for 30 min at
37C in RPMI supplemented with collagenase. Single-cell suspensions were prepared, and then cells were stained for viability with Live/Dead fixable stain followed by flow
cytometry analysis. (E) Evaluation of immune responses by IFN-g-ELISpot assay. Splenocytes were harvested and used for analysis of T cell responses 18 days
post-treatment (late stage). Three minimal epitopes from CMT64.6 sequencing were synthesized as minimal peptides to detect neoepitope-specific responses. E1b192
peptide and PepTivator (a pool of hexon peptides) were used to detect the immune response against adenovirus. The response to infected and non-infected cells (as whole
cells or lysates) was also used to measure the response to the virus (infected conditions) relative to the response to the tumor (non-infected conditions). The graph shows
representative results from 18 mice (n = 6 per group). (F) The response against the epitope Ndufs1 by each tested mouse.
Molecular Therapy: Oncolyticswas partially rescued against this isograft in the presence of the im-
mune system.
DISCUSSION
Safe and effective cancer viral therapy depends on several factors. Our
group has previously published on strategies for tumor-targeting,
tumor-selective replication, and i.t. spread of oncolytic adenoviruses.
With regard to tumor targeting, a clear advantage was shown with the
replacement of the adenovirus fiber shaft heparan sulfate proteogly-
can-binding domain by RGD12 and the insertion of an iRGD peptide
at the fiber C terminus of ICOVIR15K.6 For better i.t. spread, we
armed the adenovirus with a soluble form of the human sperm hyal-
uronidase.13 A combination of viral modification strategies, such as
the K mutation with the hyaluronidase expression in ICOVIR17K,
confirmed the value of such procedures. Here, we combined the virus
ICOVIR17K with the insertion of iRGD to generate the oncolytic
virus ICOVIR17K-iRGD.66 Molecular Therapy: Oncolytics Vol. 8 March 2018As shown in this study, the insertion of iRGD in a hyaluronidase-
armed oncolytic adenovirus led to an increased efficacy in immunode-
ficient mice. Taking into account that the infectivity and cytotoxicity
enhancement associated with iRGD was not high (Figure 1), the strik-
ing anti-tumor activity of ICOVIR17K-iRGD compared to that of the
parental ICOVIR17K observed in vivo may be explained by the
increased extravasation and tumor penetration effect of iRGD, proper-
ties that are possible in vivo only. The virus was also able to show some
efficacy in immunocompetent mice, although to a less apparent extent.
However, the immunocompetent model is limited by poor replication
of human adenovirus in mouse cells. Studies have been performed in
murine models to evaluate their permissiveness to human adeno-
virus.8,14 We used the model clone CMT64.6 in vivo, which is more
permissive than its parental model CMT64,12 though we were not
able to reduce total tumor mass or detect viral protein by immunoflu-
orescent staining ex vivo. Nonetheless, in immunocompetent mice, we
observed high polymorphonuclear infiltration that could contribute to
Figure 5. Anti-tumor Efficacy of Systemic or i.t. Administration of ICOVIR17K-iRGD in Immunodeficient Mice
Athymic nude mice bearing CMT64.6murine lung carcinoma subcutaneous tumors were treated via an i.v. or i.t. single dose of PBS or 3 1010/mouse of ICOVIR17K-iRGD.
(A) Percentage of tumor growth at the indicated days is plotted (n = 11–12). (B) Comparison of injected and non-injected contralateral tumors of the i.t. mice group. Per-
centage of tumor growth (mean ± SEM) at the indicated days is plotted (n = 5–6). (C) Immunohistochemical staining of E1A of a representative tumor treated i.t. The arrow
points to positive virus E1A staining.
www.moleculartherapy.organti-tumor efficacy and/or to virus clearance. To assess whether the
anti-tumor efficacy in the immunocompetent model could be
increased, we attempted i.t. administration. Despite clinical trials
and pre-clinical studies of oncolytic viruses, so far there are no data
about the best route of administration. Systemic administration is a
more accessible route than the i.t. one; however, toxicity, tumor selec-
tivity, and insufficient tumor delivery are caveats identified with the
use of this route. Using ICOVIR17K-iRGD in immunocompetent
mice, no differences were observed among the two routes of treatment
regarding tumor size reduction and immune infiltration. Using immu-
nohistochemistry, we were not able to detect virus at the late stage of
the experiment for any of the treatment routes, but it was detectable at
the early stage for tumors treated i.t. The systemic route had the same
efficacy as the i.t. route, though the virus was not even detected at the
early time points by the systemic route. We speculate that upon i.t.
administration, the amount of virus is higher near the injection needle
track, which favors its detection at early time points. In contrast, i.v.
administration delivers the virus at a lower concentration, which
may be insufficient to be detected by immunohistochemistry in this
semi-permissive model, but the virus may be more evenly distributed
throughout the tumor. Regardless of these possible distribution pat-
terns, it seems that the limited presence of virus during the initial
few days post-administration is sufficient to affect tumor size long
term.
Studies suggest that oncolytic adenoviruses can trigger a CD8+ T cell-
mediated anti-tumoral response.8,11 Hence, we tried to determine
whether there was a relationship between efficacy and immune infil-tration. Among the seven virotherapy-responsive neoepitopes re-
ported for the cell line CMT64,11 our clone CMT64.6 shares only
three. We detected a response toward one of these neoepitopes
(Ndufs1) in one mouse of the i.t. treated group, but the anti-tumor
efficacy was not better for this mouse compared to others of the
same group. Even though the observed response toward the epitope
was only found in one animal treated i.t., we observed an increase
in CD8+ T cells in tumors as a consequence of oncolytic virus admin-
istration. A larger number of candidate neoepitopes should be
explored to better evaluate the immune response induced by the on-
colytic adenovirus. We hypothesize that the immune system gener-
ates both anti-viral and anti-tumor adaptive immunity, though the
anti-viral response is dominant. Despite being mostly anti-viral, we
believe the immune response contributes to tumor reduction, because
we did not observe efficacy in immunocompromised mice with same
murine model CMT64.6 (Figure 5). A similar finding was observed in
a previous study with the colorectal carcinoma cell line CMT93.14 The
combination of oncolytic viruses and checkpoint inhibitors is a hot
area of preclinical and clinical research.15 This combination has
been shown to increase the immune response to neoepitopes in the
CMT64 model and to overcome the resistance to programmed cell
death protein 1 (PD1) immunotherapy.11 It will be of interest to see
whether genetic modifications related to oncolytic potency can also
increase anti-neoepitope responses.
One study demonstrated that mesenchymal stem cells (MSCs) in-
fected with oncolytic adenoviruses increase tumor-infiltrating lym-
phocytes,8 We believe that such a combination not only providesMolecular Therapy: Oncolytics Vol. 8 March 2018 67
Molecular Therapy: Oncolyticsdelivery protection to the virus but also increases anti-tumoral im-
mune responses. In addition, full virus permissiveness or replication
in the animal model could improve the prospects of eliciting anti-
tumor immunity. A study of a murine glioma model suggested that
the cell death caused by virus replication is required to induce a sig-
nificant anti-tumor immune response.16 Accordingly, the virus
ICOVIR17K-iRGD might be more effective in clinical studies in
which the replication will be more efficient than in the mouse model.
Finally, immunovirotherapy may confer benefit to other strategies
aimed at inducing anti-tumor immune responses, such as CD40L
costimulation,17 bispecific T cell engagers (BiTEs),18 incorporation
of immunostimulatory genes such as interleukin-12 (IL-12),19 or
checkpoint inhibitors.20
In summary, ICOVIR17K-iRGD was effective against human A549
tumors in immunodeficient mice. In immunocompetent mice with
syngeneic tumors, partial tumor control mediated by the immune sys-
tem was observed despite a strong anti-viral response and low repli-
cation levels. This model opens the possibility of additional studies on
the use of transgenes or combinations with other therapeutic or im-
munostimulatory agents to improve immunovirotherapy with onco-
lytic adenoviruses.MATERIALS AND METHODS
Cell Lines
Human lung adenocarcinoma A549 and murine lung carcinoma
CMT64.6 were cultured in DMEM (PAA, Les Mureaux, France) sup-
plemented with 10% fetal bovine serum (Gibco, Carlsbad, CA, USA)
and penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA). The
A549 cell line was obtained from the American Type Culture Collec-
tion (ATCC, Manassas, VA, USA). The CMT64.6 cell line was
described previously.8 All cells were routinely tested for mycoplasma.Generation of Recombinant Adenovirus
All genetic modifications were performed following a recombining
protocol adapted from Stanton et al.21 based on homologous recom-
bination in bacteria and a positive-negative selection method with the
RpsL-Neo selection cassette. To generate pAdZ-ICOVIR17K-iRGD, a
fragment containing the (GGGGS)3 linker, the iRGD peptide
(CRGDKGPDC), a stop codon, and a polyadenylation site was in-
serted, substituting for the fiber stop codon in the pAdZ-ICOVIR17K
plasmid (ICOVIR17K) carrying all genetic modifications of
ICOVIR17K. The fragment was inserted in the C terminus of
the plasmid pAdZ-ICOVIR17K, generating the new plasmid pAdZ-
ICOVIR17K-iRGD. This plasmid was transfected by the calcium
phosphate standard protocol into HEK293 cells to generate
ICOVIR17K-iRGD. The virus was plaque purified in A549 cells and
further amplified and purified following a standard cesium chloride
double-gradient protocol. Both plasmid and virus were sequenced
to confirm that they had all indicated modifications.
The generation of adenoviral vectors AdGLK and AdGLK-iRGD
containing the GFP-luciferase fusion protein under the control of a68 Molecular Therapy: Oncolytics Vol. 8 March 2018cytomegalovirus promoter substituting for the adenovirus E1 region
has been described previously.6
In Vitro Infectivity and Cytotoxicity Assays
The cell lines A549 and CMT64.6 were plated at 1  105/well in
96-well plates, and infected with different MOIs with the indicated
adenoviral vectors. After 24 hr, cells were trypsinized, and
GFP-expressing cells were quantified by flow cytometry using the
Gallios cytometer (Beckman Coulter, Indianapolis, IN). Cytotoxicity
in A549 cells was performed as described previously.6 At day 6
post-infection, the total amount of protein content was quantified
by bicinchoninic acid (Pierce Biotechnology, Rockford, IL, USA),
and the IC50 value was determined from the dose-response curve
by standard non-linear regression (GraphPad Prism 5; GraphPad,
La Jolla, CA).
Evaluation of Anti-tumor Efficacy In Vivo
In vivo studies were performed at the Institut Català d’Oncologia-
Institut de Investigació Biomèdica de Bellvitge (ICO-IDIBELL)
facility (Barcelona, Spain), AAALAC unit 1155, and approved by
IDIBELL’s Ethical Committee for Animal Experimentation. Lung
adenocarcinoma xenograft tumors were established by implanting
5  106 A549 cells subcutaneously into both flanks of 7-week-old
female athymic nude/nude (nu/nu) mice, When A549 tumors
reached 200 mm3, mice were randomized, distributed into three
groups (n = 12 tumors/group), and treated systemically with a single
dose of 200 mL of PBS or 4  1010 vp/mice of ICOVIR17K or
ICOVIR17K-iRGD, injected through the tail vein. PBS was used as
a vehicle.
Efficacy in the immunocompetent model was established by implant-
ing of 2  106 CMT64.6 into 8-week-old C57BL/6 flanks. When tu-
mors reached 100 mm3, mice were randomized, distributed into
groups (n = 12 tumors/group), and treated with PBS or 3  1010
ICOVIR17K-iRGD. PBS was used as a vehicle.
In efficacy experiments, mice were monitored twice a week. Tumor
volume was measured with a digital caliper and defined by the equa-
tion V (in cubic millimeters) = p/6W2 L, whereW and L are the
width and the length of the tumor, respectively. The two-tailed
Student’s t test was used to study the statistical significance difference
in the tumor growth between the treated groups.
ELISpot
ELISpot assays were performed to determine IFN-g release by acti-
vated splenocytes using a 96-well filtration plate with an Immobi-
lon-P membrane (MultiScreen HTS, Merck, Kenilworth, NJ, USA).
Plates were activated with 35% ethanol for 5 min, washed five
times with sterile water, incubated overnight with rat anti-mouse
IFN-g (BD AN-18, 4 mg/mL), and blocked with RPMI medium
containing 10% fetal calf serum (FCS) and penicillin-streptomycin
for at least 2 hr. A single-cell suspension of 2.5  105 splenocytes/
well was plated in 100 mL of RPMI medium including 2.5  105
tumor cells or 20 mL of tumor lysate or 200 ng of peptide. After
www.moleculartherapy.orgincubating overnight at 37C and 5% CO2, plates were washed
and stained with biotinylated anti-mouse IFN-g (BD R4-6A2,
1 mg/mL) and incubated for 2 hr, followed by streptavidin conju-
gate enzyme (E236, Sigma) and appropriate washing. After drying,
spots were counted using the ELISpot Reader (AID, Strasberg,
Germany).
The peptidesH2-Q2 (TWQLNGEEL), Rab13 (SDKKNNKCL),Ndufs1
(AAVSNMVQKI), Ppat (DPYGNRPLCM), Gsta2 (LHHFNARGRM),
chd2 (APLQNSLKEL), and Arhgef10 (AWIENPEEAI) were synthe-
sized by Biomedal (Seville, Spain), and the sequence of the peptides
was as reported.11 The peptide E1B192 (VNIRNCCY)22 was synthe-
sized by GenScript USA (Piscataway, NJ, USA). The hexon peptide
pool PepTivator AdV5 Hexon was purchased from Miltenyi Biotec
(Auburn, CA, USA). For all peptides, purification was >75%, and they
were dissolved in DMSO. The final concentration of each peptide
used for stimulation was 2 mg/mL.
Tumor-Infiltrating Lymphocytes
Tumors were mechanically disaggregated and incubated for 30 min at
37C in RPMI supplemented with 0.25 mg/mL collagenase I (Thermo
Fisher Scientific, WalthamMA) and 0.1 mg/mL DNase (Roche, Basel,
Switzerland). Single-cell suspensions were prepared by passing the di-
gested tumors through a 70-mm cell strainer. Cells were stained for
viability with Live/Dead fixable stain (Thermo Fisher Scientific), fol-
lowed by incubation with fluorescein isothiocyanate (FITC)-CD45
(30-F11) and antigen presenting cells (APCs)-CD8a (53-6.7), both
from BioLegend (San Diego, CA). Flow cytometry analysis was per-
formed with a Gallios cytometer (Beckman Coulter).
Histology and Immunohistochemistry
For immunohistochemistry in paraffin-embedded tissue, mice were
sacrificed and tumors were fixed with paraformaldehyde overnight,
and then tumors were preserved in paraffin. Sections of a 4-mm thick-
ness were cut from paraffin blocks, followed by the standard protocol.
Primary antibody incubation was performed using an anti-Ad2/5
E1A antibody (SC-430, Santa Cruz, Dallas, TX, USA) diluted 1/200
in PBS, and then slides were stained with H&E.
Statistical Analyses
Differences among groups were estimated with the two-tailed Stu-
dent’s t test or ANOVA with GraphPad Prism 5 (GraphPad, La Jolla,
CA, USA). Differences were considered statistically significant when
p < 0.05.
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